MediaTek showcases 5G satellite connectivity, smart vehicle technology

New Delhi: Fabless semiconductor company MediaTek showcased
its latest technology portfolio from its Dimensity, Filogic, Genio,
Kompanio, Pentonic, and Dimensity Auto portfolios at the India
Mobile Congress (IMC) 2023. MediaTek demonstrated its Dimensity
Auto platform that drives the future of intelligent, always-connected
vehicles through delivering impressive computing power and wideranging
technologies. The showcase included MediaTek powered devices
across diverse verticals from some of the world’s biggest brands.
MediaTek Dimensity Auto drives the future of intelligent, alwaysconnected
vehicles enabling smart vehicle technology innovation through
delivering impressive computing power and comprehensive technologies.
MediaTek Dimensity Auto includes Dimensity Auto Cockpit,
Dimensity Auto Connect, Dimensity Auto Drive, and Dimensity Auto
Components.MediaTek’s 3GPP standards-based 5G Non-Terrestrial Network
(NTN) solution brings two-way satellite communications to
smartphones and other devices. Some of the devices powered by
MediaTek’s NTN solutions includes Motorola defy 2 smartphone and
Motorola defy satellite link. The MediaTek Dimensity flagship 5G
family includes Dimensity 9200+, 9200, 9000+ and 9000 system-onchips
(SoCs). MediaTek showcased smartphones including the newly
launched OPPO Find N3 Flip, Vivo X90 powered by MediaTek
Dimensity 9200, OnePlus Nord 3 5G powered by MediaTek Dimensity
9000, Tecno Phantom V Fold powered by MediaTek Dimensity 9000+,
Tecno Phantom V Flip powered by MediaTek Dimensity 8050 and
Motorola Edge 40 Neo powered by MediaTek Dimensity 7030, among
others. Devices across digital TVs, smart speakers, Wi-Fi routers, armbased
Chromebooks and other smart home products including
Primebook, Jiobook, and HP Chromebook, portable projectors from
MyBox and Wanbo, Lenovo smart clock, Amazon Echo, Amazon Fire
TV Stick, Airoha’s Bluetooth headsets and FireBoltt Artilery Fitness
Smartwatch, PayTm Soundbox, iMin PoS Terminals and PeopleTech
IoT bike powered by MediaTek chipset.On showcase were connectivity solutions including routers, accesspoints, mesh systems powered by MediaTek Filogic and 5G broadband
section powered by MediaTek T750 5G platform which is designedfor CPE devices that can providefixed wireless access in gateways,routers, and mobile hotspot devices.Sun Pharma and Zydus Lifesciencesenter into licensing agreementHyderabad/Mumbai: SunPharmaceutical IndustriesLimited, and includes itssubsidiaries and/or associatecompanies) and Zydus
Lifesciences Limited (includingits subsidiaries/affiliateshereafter referred to as “Zydus”), on Monday announced thatboth companies have entered intoa licensing agreement to comarket
an innovative drug,Desidustat in India. Desidustatis first-of-its-kind oral treatmentfor anemia associated withChronic Kidney Disease (CKD)in India, the pharmaceuticalcompany said in a release. Underthe agreement, Zydus has grantedSun Pharma semi-exclusive rightsto comarket the product in India.Sun Pharma will market the drugunder the brand nameRYTSTAT®. Zydus launchedthe drug under the brand nameOxemia™ in 2022 and willcontinue to market it. Zydus willreceive upfront licensing incomeand is eligible to receivemilestone income based on
achievement of pre-definedmilestones. Commenting on thedevelopment, Kirti Ganorkar,
CEO – India Business, SunPharma said, “The addition ofRYTSTAT® further strengthens
our nephrology portfolio inIndia. This partnership willallow greater access to a critical
therapy, helping millions ofpatients suffering from ChronicKidney Disease. At Sun, it has
always been our endeavour tointroduce innovative productsthat help improve the quality of
life of patients.” A spokespersonfrom Zydus Lifesciences Limitedsaid, “Desidustat, which is one
of the critical treatment optionsfor CKD patients, hassubstantially improved the
patients’ quality of life since it ismore convenient to take an oralpill instead of an injection thatneeds to be administered. We arepleased to join hands with SunPharma to expand the reach ofthis novel medicine by enablingaccess to more patients.” Morethan 115 million people in India
suffer from CKD, predicted tobecome one of the most commoncauses of premature death by
2040 globally. The clinicaldevelopment programme ofDesidustat was one of the largest
trials of its kind in India for anemiain CKD patients, conducted inover 1200 subjects. Desidustat
provides CKD patients with anoral, convenient therapeuticoption for the treatment of anemia.
SECL Achieves 100 milliontonne Coal DispatchNew Delhi(PIB): Coal Indiasubsidiary South EasternCoalfields Ltd (SECL)hasachieved 100 million tonne (MT)coal dispatch for FY 2023-24.
This is the fastest 100 MT coaldispatch achieved by Chhattisgarhbased company since its
inception. Last year, SECL haddispatched around 85 milliontonne coal in the same period and
thus during this financial year thecompany has registered a growthof 17.65%.Of the total coal dispatch, morethan 80% went to the powersector as the company dispatchedaround 81 million tonnes of coalto power plants across thecountry. This is a significantachievement keeping in mind theupcoming festival season whenpower demand is set to peak.SECL mega projects Gevra,
Dipka, and Kusmunda located inKorba district have contributedsignificantly to the total dispatch
of 100 million tonnes of coal.Gevra, the largest coal mine in thecountry has contributed 30.3 MT
while Dipka and Kusmundacontributed 19.1 MT and 25.1MT of coal respectively. The totalshare of all three mega projects inthe total dispatch has been morethan 74 percent.Apart from this, SECL’s KoreaRewa coalfield, where most of theold and underground mines arelocated, also made notablecontribution by enhancing coaldispatch by 20% as compared tolast year.SECL is one of the largest coalproducing subsidiaries of CoalIndia. The company produced 167MT of coal (highest in its history)and accounted for around onefourthof CIL’s total coalproduction in FY 22-23. Thisyear the company has a target of197 MT of coal production.

About Post Author